Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry
© 2024. The Author(s)..
BACKGROUND: The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platinum-based regimens' safety and synergy with combination treatments need consideration.
METHODS: We analyzed cases from the AGAMENON-SEOM Spanish registry of HER2-negative advanced esophagogastric adenocarcinoma treated with platinum and fluoropyrimidine from 2008 to 2021. This study focused exclusively on patients receiving one of the four regimens: FOLFOX (5-FU and oxaliplatin), CAPOX (capecitabine and oxaliplatin), CP (capecitabine and cisplatin) and FP (5-FU and cisplatin). The aim was to determine the most effective and tolerable platinum and fluoropyrimidine-based chemotherapy regimen and to identify any prognostic factors.
RESULTS: Among 1293 patients, 36% received either FOLFOX (n = 468) or CAPOX (n = 466), 20% CP (n = 252), and 8% FP (n = 107). FOLFOX significantly increased PFS (progression free survival) compared to CP, with a hazard ratio of 0.73 (95% CI 0.58-0.92, p = 0.009). The duration of treatment was similar across all groups. Survival outcomes among regimens were similar, but analysis revealed worse ECOG-PS (Eastern Cooperative Oncology Group-Performance Status), > 2 metastatic sites, bone metastases, hypoalbuminemia, higher NLR (neutrophil-to-lymphocyte ratio), and CP regimen as predictors of poor PFS. Fatigue was common in all treatments, with the highest incidence in FOLFOX (77%), followed by FP (72%), CAPOX (68%), and CP (60%). Other notable toxicities included neuropathy (FOLFOX 69%, CAPOX 62%), neutropenia (FOLFOX 52%, FP 55%), hand-foot syndrome in CP (46%), and thromboembolic events (FP 12%, CP 11%).
CONCLUSIONS: FOLFOX shown better PFS than CP. Adverse effects varied: neuropathy was more common with oxaliplatin, while thromboembolism was more frequent with cisplatin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - (2024) vom: 15. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Advanced esophagogastric cancer |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12094-024-03388-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368512177 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368512177 | ||
| 003 | DE-627 | ||
| 005 | 20240216232934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-024-03388-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1296.xml |
| 035 | |a (DE-627)NLM368512177 | ||
| 035 | |a (NLM)38361134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arias-Martinez, Aranzazu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platinum-based regimens' safety and synergy with combination treatments need consideration | ||
| 520 | |a METHODS: We analyzed cases from the AGAMENON-SEOM Spanish registry of HER2-negative advanced esophagogastric adenocarcinoma treated with platinum and fluoropyrimidine from 2008 to 2021. This study focused exclusively on patients receiving one of the four regimens: FOLFOX (5-FU and oxaliplatin), CAPOX (capecitabine and oxaliplatin), CP (capecitabine and cisplatin) and FP (5-FU and cisplatin). The aim was to determine the most effective and tolerable platinum and fluoropyrimidine-based chemotherapy regimen and to identify any prognostic factors | ||
| 520 | |a RESULTS: Among 1293 patients, 36% received either FOLFOX (n = 468) or CAPOX (n = 466), 20% CP (n = 252), and 8% FP (n = 107). FOLFOX significantly increased PFS (progression free survival) compared to CP, with a hazard ratio of 0.73 (95% CI 0.58-0.92, p = 0.009). The duration of treatment was similar across all groups. Survival outcomes among regimens were similar, but analysis revealed worse ECOG-PS (Eastern Cooperative Oncology Group-Performance Status), > 2 metastatic sites, bone metastases, hypoalbuminemia, higher NLR (neutrophil-to-lymphocyte ratio), and CP regimen as predictors of poor PFS. Fatigue was common in all treatments, with the highest incidence in FOLFOX (77%), followed by FP (72%), CAPOX (68%), and CP (60%). Other notable toxicities included neuropathy (FOLFOX 69%, CAPOX 62%), neutropenia (FOLFOX 52%, FP 55%), hand-foot syndrome in CP (46%), and thromboembolic events (FP 12%, CP 11%) | ||
| 520 | |a CONCLUSIONS: FOLFOX shown better PFS than CP. Adverse effects varied: neuropathy was more common with oxaliplatin, while thromboembolism was more frequent with cisplatin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Advanced esophagogastric cancer | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Fluoropyrimidine | |
| 650 | 4 | |a Oxaliplatin | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Martínez de Castro, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Arrazubi, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Custodio, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Montes, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Diez, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Limón, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Juana María |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal-Tocino, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Macias, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Visa, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Martin Richard, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Sauri, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Hierro, Cinta |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Cerda, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Moreno, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Lago, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a Mérida-García, Antonio José |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez González, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a García Navalón, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz Martín, Maribel |e verfasserin |4 aut | |
| 700 | 1 | |a Marín, Gema |e verfasserin |4 aut | |
| 700 | 1 | |a López-López, Flora |e verfasserin |4 aut | |
| 700 | 1 | |a Ruperez Blanco, Ana Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández, Alejandro Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona-Bayonas, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez-Manceñido, Felipe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g (2024) vom: 15. Feb. |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-024-03388-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 02 | ||